Einträge von Launay, Odile auf dem Publikationsserver
![]() | Eine Stufe nach oben |
Gehe zu: Artikel
Anzahl der Einträge: 2.
Artikel
Silvestri, Guido, Lévy, Yves
, Lacabaratz, Christine, Ellefsen-Lavoie, Kim, Stöhr, Wolfgang, Lelièvre, Jean-Daniel, Bart, Pierre-Alexandre, Launay, Odile, Weber, Jonathan, Salzberger, Bernd, Wiedemann, Aurélie, Surenaud, Mathieu, Koelle, David M., Wolf, Hans, Wagner, Ralf, Rieux, Véronique, Montefiori, David C., Yates, Nicole L., Tomaras, Georgia D., Gottardo, Raphael, Mayer, Bryan, Ding, Song, Thiébaut, Rodolphe, McCormack, Sheena, Chêne, Geneviève und Pantaleo, Giuseppe
(2020)
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
PLOS Pathogens 16 (6), e1008522.
Volltext nicht vorhanden.
, Lacabaratz, Christine, Ellefsen-Lavoie, Kim, Stöhr, Wolfgang, Lelièvre, Jean-Daniel, Bart, Pierre-Alexandre, Launay, Odile, Weber, Jonathan, Salzberger, Bernd, Wiedemann, Aurélie, Surenaud, Mathieu, Koelle, David M., Wolf, Hans, Wagner, Ralf, Rieux, Véronique, Montefiori, David C., Yates, Nicole L., Tomaras, Georgia D., Gottardo, Raphael, Mayer, Bryan, Ding, Song, Thiébaut, Rodolphe, McCormack, Sheena, Chêne, Geneviève und Pantaleo, Giuseppe
(2020)
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
PLOS Pathogens 16 (6), e1008522.
Volltext nicht vorhanden.
Launay, Odile, Duval, Xavier, Fitoussi, Serge, Jilg, Wolfgang, Kerdpanich, Angkool, Montellano, May, Schwarz, Tino F., Watanveerade, Veerachai, Wenzel, Jürgen J.
, Zalcman, Gerard, Bambure, Vinod, Li, Ping, Caplanusi, Adrian, Madan, Anuradha, Gillard, Paul und Vaughn, David W.
(2013)
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
BMC Infectious Diseases 13 (1).
